As our sequencing analysis of advanced HER2 + breast tumors identified recurrent mutations in multiple MAPK pathway members (Fig. 1a), we asked whether pathway activation through mutational mechanisms other than NF1 loss also promotes resistance to HER2i. The gene discussed is NF1; the disease is breast neoplasm.